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In Brief
Analogues of glucagon-like peptide-1 (GLP-1) are used to treat diabetes for their blood glucose lowering effects. Koehler et al. now show that GLP-1 also promotes gut growth through Fgf7 and that loss of GLP-1 signaling reduces growth in models of gut hyperplasia and tumorigenesis.
INTRODUCTION
Gut peptides act as circulating hormones or neurotransmitters to control appetite, gastrointestinal motility, gall bladder emptying, pancreatic enzyme secretion, and the absorption and disposal of ingested nutrients. The proglucagon-derived peptides (PGDPs), encompassing glicentin, oxyntomodulin, GLP-1, and glucagonlike peptide-2 (GLP-2), are among the best-studied products of the enteroendocrine L cell and regulate energy ingestion, absorption, and disposal (Campbell and Drucker, 2013; Drucker and Yusta, 2014) . Analogues of GLP-1 and GLP-2 have been approved for the treatment of diabetes and short bowel syndrome, respectively, further highlighting conservation of key metabolic pathways linking gut peptide action to the control of energy homeostasis.
GLP-1 is classically viewed as an incretin that rapidly augments glucose-dependent insulin secretion following meal ingestion.
GLP-1 also inhibits glucagon secretion, gastric emptying, and food intake, leading to reduction of glycemia and weight loss. Despite the distal location of most GLP-1-producing L cells in the ileum and colon, GLP-1 levels rise rapidly within minutes of meal ingestion, findings attributed to direct secretion from a subset of L cells in the jejunum and a proximal-distal neuroendocrine axis that communicates signals enabling secretion of PGDPs from the ileum and colon.
Several alternative explanations have arisen for the role and location of distal gut L cells. Colonic L cells may function as an energy sensor, secreting GLP-1 to modulate gut motility in response to fatty acids and energy availability (Wichmann et al., 2013) . Alternatively, distal L cells may liberate GLP-1 in response to microbial byproducts (Molina et al., 2014) , or other metabolites from digested nutrients (Reimann et al., 2012) . A third role for GLP-1 in the distal gut includes stimulation of SB growth (Kissow et al., 2012; Simonsen et al., 2007) ; however, mechanisms linking GLP-1R signaling to augmentation of mucosal growth remain obscure.
Here, we demonstrate that gain and loss of GLP-1R signaling modulates intestinal growth in the SB and large bowel (LB). Intestinal growth in Gcgr À/À mice was differentially reduced in 
:Apc
Min/+ mice. These findings extend current concepts of GLP-1 action in the distal gut to encompass control of intestinal growth.
RESULTS

Endogenous GLP-1 and GLP-2 Independently Mediate Intestinal Growth
We first assessed whether endogenous native GLP-1, acting through the canonical GLP-1R, is capable of promoting bowel growth in Gcgr in Gcgr À/À mice (Figures S1A and S1B), consistent with elevations in GLP-2, a peptide with known intestinotrophic activity (Drucker and Yusta, 2014; Gelling et al., 2003) . Nevertheless, SB weight and length were reduced, but not normalized, while LB mass and length remained elevated in Gcgr À/À :Glp2r À/À mice ( Figure S1B ). Elimination of the GLP-1R failed to normalize SB weight. However, SB length and LB weight and length were normalized in Gcgr À/À :Glp1r À/À mice ( Figure S1A ). Hence, GLP-1R signaling independent of the GLP-2R mediates trophic effects predominantly in the distal gastrointestinal tract of Gcgr À/À mice.
GLP-1R Activation Promotes Intestinal Growth by Increasing Crypt Number
To identify mechanisms through which GLP-1R signaling promotes gut growth independent of confounding metabolic perturbations arising in Gcgr À/À mice (Gelling et al., 2003) , we treated C57BL/6 WT mice with the clinically approved GLP-1R agonist exenatide (Ex-4: exendin-4) for 1 week. Ex-4 markedly increased the weight, length, and weight per unit length of the SB and significantly augmented LB weight (Figures 1A and S1C) . Furthermore, the intestinotrophic effects of Ex-4 and a longacting human GLP-1R agonist, liraglutide, were mediated through the GLP-1R, as they had no effect on bowel growth in Glp1r À/À mice (Figures 1B, S1D, and S1E). Although GLP-2 induces intestinal growth by increasing crypt cell proliferation (Drucker et al., 1996) , Ex-4 did not enhance cell proliferation in the crypt compartment of the jejunum ( Figure 1C ) or colon (Figure S1F) . In contrast, EGF increased the number of BrdU+ cells in the intestinal stem (ISC) region and in the transit amplifying (TA) region ( Figure 1C ), suggesting that GLP-1R signaling induces intestinotrophic effects through mechanisms that diverge from those activated by GLP-2 or EGF.
To determine whether the intestinotrophic actions of GLP-1R agonists are sustained with chronic administration, we treated mice with Ex-4 twice daily for 1 month. Ex-4 increased SB weight and length (Figures 1D and S1G) and increased the circumference and crypt number in the proximal ( Figure 1E , duodenum and jejunum), but not the most distal region of the SB ( Figure 1E , distal ileum). Similarly, Ex-4 significantly increased the number of crypts/cross-section in the colon ( Figure 1E ). In contrast, chronic Ex-4 treatment did not increase colon crypt depth or SB crypt + villus height ( Figure 1E ). These results suggest that sustained GLP-1R activation increases crypt number, but not crypt cell proliferation, to promote intestinal growth. Consistent with independent contributions of endogenous GLP-1 and GLP-2 on bowel growth in Gcgr À/À mice (Figures S1A and S1B), coadministration of the GLP-2R agonist h[Gly 2 ]GLP-2 (Drucker et al., 1997) and Ex-4 significantly increased SB weight and length to a greater extent than either peptide alone (Figures 1F and S1H) . Furthermore, histological examination revealed that whereas jejunal circumference was increased by Ex-4, GLP-2 increased villus length ( Figure 1G ). Taken together, whereas GLP-2 promotes intestinal growth by inducing crypt cell proliferation and villus elongation (Drucker and Yusta, 2014) , GLP-1R agonism promotes crypt fission and augments crypt number, resulting in an increase in the width and length of the intestine.
GLP-1R Signaling Controls Polyp Burden in Apc
Min/+ Mice Subjects with obesity or type 2 diabetes exhibit increased rates of colon cancer (Calle and Thun, 2004; Lai et al., 2013; Li et al., 2011) . Hence, we examined GLP1R expression in human colon tumors. The GLP1R ( Figure 2A ) and both the GLP2R and glucose-dependent insulinotropic polypeptide receptor (GIPR) mRNA transcripts (Figures S2A and S2B) were expressed in human colorectal tumors, but at lower levels relative to those in adjacent non-neoplastic colon samples from the same patients. Glp1r transcripts were also detected in colon polyps from Apc Min/+ mice, a murine model of intestinal tumorigenesis (Figures 2B and S3E) , at lower levels relative to normal adjacent colon or duodenum tissue ( Figure 2B) . Hence, the GLP-1R is not upregulated in benign or malignant intestinal lesions of epithelial origin. Nevertheless, Ex-4 significantly increased the number ( Figures 2C and S3A ) and size ( Figures 2D and S3B ) of polyps primarily in the distal SB of female ( Figure 2 ) and male ( Figure S3 ) Apc Min/+ mice. In contrast, Ex-4 had no effect on polyp burden in more proximal regions of the SB or on the number or size of polyps or aberrant crypt foci (ACF) in the colon (Figures 2E, 2F, S3C, and S3D) .
To examine the physiological importance of the endogenous GLP-1/GLP-1R system for polyp growth, we generated , and SB weight (as a percentage of body weight), length, and weight/unit length (right panels). n = 10 in each group from three experiments. (E) Circumference surrounding the mucosa, number of crypts/cross section, and crypt + villus height (for SB), or crypt depth (for colon) are shown for each section of intestine as indicated. Schematic representation of the locations of the sections used for histology (H) is depicted above the data. n = 6-7 mice in each group. (F) SB weight (as a percentage of body weight), length, and weight/unit length in C57BL/6 male mice following administration of PBS, Ex-4, Gly2-GLP-2 (GLP-2), or both Ex-4 and Gly2-GLP-2 (Ex-4/GLP-2) for 10 days. n = 5 in each group. (G) Representative histological sections of jejunum stained with H&E from mice treated with PBS, Ex-4, Gly2-GLP-2 (GLP2), or both, as indicated. n = 5 in each group. Magnification 340. For (A)-(F), data are means ± SE. *p < 0.05, **p < 0.01, ***p < 0.001 versus PBS. #p < 0.05, ##p < 0.01, ###p < 0. ]GLP-2. See also Figure S1 . (Drucker et al., 1996) , acute Ex-4 administration reduced cell proliferation in SB polyps and decreased basal crypt cell proliferation in the jejunum, but not the colon, of Apc Min/+ mice ( Figure 2K ). In contrast, chronic Ex-4 treatment reduced the number of apoptotic cells but had no effect on neutrophil infiltration in SB polyps ( Figures S3F and S3G ). Acute Ex-4 administration increased the phosphorylation/inactivation of GSK3 in colonic polyps ( Figure S3H ), whereas chronic Ex-4 treatment increased expression of Wnt target genes (axin2, lef1, tcf7) and the ligand Wnt5a in colon polyps of Apc Min/+ mice ( Figure 2L ). Moreover, levels of mRNA transcripts encoding the ISC markers musashi-1 (msi-1) and achaete-scute complex-like-2 (ascl2) were upregulated in colon polyps of chronically Ex-4-treated Apc Min/+ mice ( Figure 2L ) as well as in the jejunum of C57BL/6 mice upon chronic Ex-4 exposure ( Figure S5A Table S1 . Ex-4 upregulated Igf1 transcripts in the jejunum and colon and areg and ereg in the jejunum of C57BL/6 mice ( Figure 3A ) as well as Igf1r and areg in the duodenum of WT ( Figure S5C ) and Apc Min/+ mice (Table   S1 ). Ex-4 also acutely induced ereg mRNA levels in colon polyps of Apc Min/+ mice ( Figure 3B ) as well as tcf7 and tcf7l2 transcripts in the jejunum of C57BL/6 mice ( Figure S5B ). These findings suggested that GLP-1R activation may induce receptor tyrosine kinase IGF1R/ErbB(EGFR) (igf1, areg, ereg) pathways to regulate intestinal growth and tumorigenesis. We therefore examined whether the intestinal growth-promoting effects of Ex-4 or liraglutide were preserved in (i) mice with a conditional deletion of the IGF-1R from intestinal epithelial cells (IE-Igf1rKO) (Rowland et al., 2011) and (ii) Egfr wa2/wa2 (waved) mice harboring a lossof-function point mutation in the EGFR kinase domain (Luetteke et al., 1994) . Liraglutide increased SB weight and length in IEIgf1rKO mice, and colon weight trended higher in liraglutidetreated IE-Igf1rKO and littermate control mice ( Figure 3C ). Ex-4 also increased SB weight, and colon weight trended higher after Figure S5E ) or in the jejunum after chronic administration ( Figure S5D ), Ex-4 acutely increased Fgf7 mRNA levels in the small bowel of WT mice ( Figure 4A ) and in colon polyps of Apc Min/+ mice ( Figure 4B) Min/+ mice; expression of the receptor for Fgf7, Fgfr2IIIb, was also detected in RNA from colon and colonic polyps, and both FGF7 and FGFR2 mRNA transcripts were detected in RNA from normal colon and human colonic adenocarcinoma ( Figures 4H and 4I ), in agreement with previous analyses (Otte et al., 2000) . These experiments suggest that enhanced or disrupted GLP-1R signaling modifies normal and neoplastic intestinal growth via a GLP-1R-Fgf7 axis.
Overlapping Intestinal Gene Expression Profiles
Regulated by Ex-4 and Fgf7/Kgf To identify growth-related signaling pathways activated by GLP-1R agonists and/or Fgf7 in the gut, we carried out microarray (Illumina WG-6) analysis on jejunal RNA prepared from mice 1 hr, 5 hr, and 20 hr following a single dose of Ex-4 or Fgf7. The number of genes significantly upregulated or downregulated at least 1.2-fold by Ex-4 or Fgf7 is shown in Figure 5A . Real-time PCR independently verified that several genes were regulated by both Ex-4 and Fgf7, including phlda1 (pleckstrin homology-like domain, family A, member 1), asns (asparagine synthetase), pcsk9 (proprotein convertase subtilisin/kexin type 9), mthfd2 (methylenetetrahydrofolate dehydrogenase [NAD+ dependent]), Table S1 .
fkbp11 (FK506 binding protein 11), gar1 (GAR1 ribonucleoprotein homolog), and adck5 (aarF domain containing kinase 5) (Figure 5B) . In contrast, Fgf7, but not Ex-4, induced the expression of egr-1 (early growth response 1) and tff2 (trefoil factor 2), whereas Ex-4, but not Fgf7, upregulated levels of mmp13 (matrix metallopeptidase 13) and Reg3b (regenerating islet-derived protein III beta) RNA transcripts ( Figure 1994; Chen et al., 2002) . To address whether IELs link GLP-1R signaling to Fgf7 expression and gut growth, we generated bone marrow chimeras by reconstituting lethally irradiated Glp1r +/+ and Glp1r À/À mice with congenic bone marrow from Glp1r +/+ donor mice. Donor chimerism, determined by flow cytometry 14-16 weeks after transplant, was 95.9% ± 0.8% and 80.8% ± 4.6% in spleen and purified small intestinal IELs from recipient mice, respectively ( Figure 6A ). Analysis of Glp1r expression independently confirmed that IELs derived from transplanted marrow repopulated the intestinal compartment ( Figure 6B ). The reconstitution efficiency of Glp1r expression in the jejunum and purified IELs of Glp1r À/À recipients was 75% ± 21.4% and 90.7% ± 22.9%, respectively ( Figure 6B ). Nevertheless, Ex-4 did not induce intestinal growth in Glp1r À/À recipient mice, despite efficient reconstitution of Glp1r +/+ IELs into Glp1r À/À recipient mice ( Figure 6C ). Furthermore, levels of Fgf7 mRNA transcripts were extremely low ($1,000-fold lower than Glp1r) in sorted small intestinal IELs (>98% purity), even following in vitro activation (data not shown). In contrast, Fgf7 mRNA transcripts were enriched in RNA from primary SB myofibroblast cultures, compared with RNA isolated from jejunum ( Figure 6D ). Although we detected a gene expression profile consistent with that previously reported for myofibroblasts in RNA from these cultures ( Figure 6D ), Glp1r mRNA transcripts were not expressed at significant levels. Hence, although Fgf7+ myofibroblasts remain a potential downstream target for GLP-1R-dependent control of gut growth, it seems likely that and Egfr wa2/wa2 mice treated with Ex-4 or PBS for 7 days. n = 5 (PBS) or n = 6 (Ex-4) mice for each genotype. Data are means ± SE from two experiments. *p < 0.05, **p < 0.01 versus PBS. See also Figure S5 and Table S1 .
one or more additional GLP-1R+ cell types, perhaps enteric neurons, are important for conveying GLP-1R-activated signals to Fgf7-dependent stimulation of intestinal growth.
DISCUSSION
Although pharmacological administration of GLP-1R agonists increased the mass of the rodent SB epithelium, mechanisms connecting GLP-1R activation to intestinal growth were not identified (Kissow et al., 2012; Simonsen et al., 2007) . We demonstrate that enhanced GLP-1R signaling in Gcgr À/À mice also mediates intestinotrophic activity not only in the SB, but also in the colon. Importantly, increased colonic growth and SB length evident in Gcgr À/À mice were completely normalized . Surprisingly, GLP-1R agonists did not increase crypt cell proliferation; rather, they expanded the mass of the epithelium through stimulation of crypt fission. Although mechanism(s) regulating crypt division/fission are not well defined, intestinal mucosal growth primarily occurs via crypt division in neonatal humans and rodents, whereas crypt fission occurs at very low rates in normal adult tissue. In contrast, crypt fission is induced in the adult intestine as part of the regenerative process following intestinal damage, including ulcerative colitis, surgical resection, or irradiation (Plamboeck et al., 2013a) . Moreover, acquisition of a single Apc-deficient crypt is not sufficient to promote tumorigenesis, but rather a 'field' of adjacent mutated crypts, arising through crypt fission or independent neighboring events, is necessary for tumor initiation (Ali et al., 2015; Plamboeck et al., 2013b) . Furthermore, intestinal crypts harboring oncogenic mutations can further expand through enhanced crypt fission in both the murine (Snippert et al., 2014) Complementary evidence for a subset of pathways regulated by both GLP-1R agonists and Fgf7 derives from microarray and gene expression studies, which identified intestinal genes coregulated by Fgf7 and Ex-4. We pursued the possibility that Glp1r expression in IELs may liberate Fgf7, which in turn promotes gut growth. Nevertheless, we were unable to restore GLP-1R-dependent intestinal growth following reconstitution of GLP-1R+ IELs in Glp1r À/À mice. Although limitations in the sensitivity and specificity of reagents for detection of the murine GLP-1R (Panjwani et al., 2013) and Fgf7 proteins limit current efforts to more precisely localize cell types linking GLP-1R signaling to Fgf7-dependent stimulation of gut growth, we did observe Fgf7 expression in mouse SB myofibroblasts, whereas levels of Glp1r mRNA transcripts were barely detectable in SB myofibroblast RNA. The GLP-1R has been localized to the enteric nervous system (ENS) in mice (Richards et al., 2014) and primates (Pyke et al., 2014) , and FGF7 has been detected in the human ENS, raising the possibility that the ENS communicates a GLP-1R-dependent signal that converges on Fgf7 and ultimately promotes crypt fission. Although acute activation of GLP-1R signaling in enteric neurons rapidly propagates a signal to the intestinal mucosal epithelium, the precise downstream effectors of these signals remain unclear (Kedees et al., 2013) . Similarly, the specific cell types and molecular mediators connecting intestinal GLP-1R signaling to Fgf7 and crypt fission require further clarification.
The demonstration that the Fgf7/Fgfr2 axis is an important target for the intestinotrophic actions of GLP-1R agonists raises questions with translational implications. Although human subjects with type 2 diabetes and obesity exhibit increased rates of multiple cancers, incretin-based therapies have not been reported to increase cancer incidence, and GLP-1R agonists frequently produce weight loss, which may reduce the incidence of cancer (Ashrafian et al., 2011; Terzi c et al., 2010) . Whether long-term use of GLP-1R agonists will modify cancer risk in obese and/or diabetic subjects is unknown and will require analysis of large numbers of treated subjects, likely from registry studies.
Following bariatric surgery or genetic reduction of Gcgr signaling, levels of GLP-1, GLP-2, and bile acids are increased (Madsbad et al., 2014) . Combined use of GLP-1 and GLP-2R agonists for the treatment of short bowel syndrome has also been examined (Madsen et al., 2013 transcripts, whereas the assay targeting exons 5-6 exclusively detects the wild-type Glp1r mRNA. Glp1r transcript levels are expressed relative to the Glp1r mRNA levels in Glp1r +/+ recipient mice (gray horizontal stripe).
(C) Small bowel (SB) weight (as a percentage of tibia length), length (relative to tibia length), SB weight/unit length, and tibial length of recipient Glp1r +/+ and Glp1r À/À mice 14-16 weeks after reconstitution treated with PBS or Ex-4 for 10 days. n = 8-10 males per group. Shown are combined data from two independent bone marrow transfer experiments. Data are means ± SE. *p < 0.05 versus PBS.
(D) qPCR analysis of RNA isolated from jejunum (Jej), or primary cultures of myofibroblasts (Myofib) prepared from mouse small intestine. Gene expression was assessed on cells at passage 3. Data are means ± SD from two independent experiments, comprised of two separate cultures, each derived from a separate mouse (n = 4 cultures).
treated with bariatric surgery revealed a significantly increased incidence of colorectal cancer, relative to obese control subjects (Derogar et al., 2013) . Moreover, the incidence rate for development of colorectal cancer progressively increased with length of time after bariatric surgery (Derogar et al., 2013) . However, the importance and mechanistic underpinning of these findings remains unclear and will require additional investigation. Apc Min/+ mice represent the most widely used genetically defined murine model for intestinal tumorigenesis and harbor a genetic mutation in the gene underlying the development of colon cancer in human subjects with familial adenomatous polyposis (Nishisho et al., 1991 
Glucose Tolerance Tests and Assessment of Gastric Emptying
Glucose tolerance (8-11 weeks old) and acetaminophen absorption (12-15 weeks old) tests to assess gastric emptying were carried out Fgf7 +/+ or Fgf7 À/À mice as described (Lamont et al., 2012) .
Statistical Analysis
Results are expressed as mean ± SE. Statistical significance was assessed by one-way or two-way ANOVA using Bonferroni's multiple comparison post test and, where appropriate, by unpaired Student's t test using GraphPad Prism 5 (GraphPad Software). Data were excluded from analysis if considered an outlier by the Grubbs' test (GraphPad Software). A p value < 0.05 was considered to be statistically significant.
ACCESSION NUMBERS
The NCBI GEO accession number for the microarray data reported in this paper is GSE63841. 
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
Supplemental Experimental Procedures
Time course studies: Non-fasted male C57BL/6 mice (8-9 weeks-old) were injected sc with a single dose of Ex-4 (1 g), EGF (0.5 mg/kg) or vehicle (PBS), and mice were killed 15, 30, 45, 60, or 90 min later by cervical dislocation. Alternatively, male C57BL/6 mice (11 weeks-old)
were injected with Ex-4 for 4 h, or 24 h-7 days. Non-fasted mice were euthanized by CO 2 inhalation 4 h after the initial injection, or the morning following the last injection (~12 h after the last injection) for the 24 h-7 day time points. Blood samples were collected by cardiac puncture, chilled in the presence of 10% TED (v/v) (5000 kIU/ml Trasylol (Bayer), 1.2 mg/ml EDTA, and 0.1 nmol/l Diprotin A (Sigma Chemical Co., St. Louis, MO), and plasma was stored at -80°C.
Tissue collection, morphometry, immunohistochemistry, and polyp evaluation:
Following euthanasia, mice were weighed, the entire GI tract from the stomach to the rectum was removed, and gut weight and length was determined. Adjacent 2-cm intestinal segments from the SB and colon were fixed in 10% neutral-buffered formalin and paraffin embedded or snap-frozen in liquid nitrogen and stored at −70 ⁰C. Tibial length was measured using an electronic caliper. To assess polyp burden, Apc Min/+ and WT littermate control mice (6-9 week old) were administered exogenous Ex-4 or PBS for 4 weeks. Alternatively, 11 week old Apc Min/+ /Glp1r +/+ and Apc Min/+ /Glp1r −/− littermate mice were assessed. The entire small intestine and colon were examined for polyps and for aberrant crypt foci (colon) as described (Koehler et al., 2008) .
Immunohistochemistry and morphometry were done on 5-μm histological sections stained with hematoxylin and eosin (H&E) (Yusta et al., 2012) . Sections were scanned using the Scanscope CS system (Aperio Technologies) at x20 magnification and digital images analyzed using Scanscope software (Aperio Technologies). The circumference surrounding the mucosa (encircling the area between the bottom of the crypts and the top of the submucosa) and the number of crypts/cross section were measured. To assess intestinal crypt cell proliferation,
Apc
Min/+ and WT littermate control mice (8-12 weeks-old) were injected twice (3 h apart) with Ex-4, EGF (0.5 mg/kg, ip), or PBS followed by a single ip injection of 5-bromo-2′-deoxyuridine (BrdU) (Sigma-Aldrich; 100 mg/kg, dissolved in PBS) 1 h before death. BrdU immunopositivity and the incidence of BrdU staining at each cell position within the crypt were scored as described (Yusta et al., 2012) . The level of apoptosis (TUNEL positive cells) or inflammation in SB polyps neutrophils (CL-8993AP, Cedarlane) was quantified.
Generation of Bone Marrow Chimeras, Isolation of Mouse Intestinal Intraepithelial
Lymphocytes (IELs) and Splenocytes, and Myofibroblast Cultures:
Bone marrow chimeras were generated by lethally irradiating Glp1r +/+ or Glp1r -/-CD45.2 + recipient male mice (1100 cGy, split into two equal doses administered 4 hours apart) followed by tail vein injection of 5 x 10 6 congenic bone marrow cells from donor WT (Glp1r Mouse splenocytes were isolated by mechanical dissociation of the spleen followed by red blood cell lysis. Primary cultures of myofibroblasts were prepared from mouse small intestine as described (Shaker et al., 2010) . Gene expression was assessed on cells at passage 3.
RNA isolation, quantitative real-time RT-PCR, Southern and Western blot analysis:
Human Phospho-c-myc (Ser-62, ab51156) was from Abcam, Cambridge, MA and used at a 1:1000 dilution. c-myc (9E10) was from Santa Cruz Biotechnologies (1:1000) , Santa Cruz, CA.
Microarray Analysis:
Non-fasted male C57BL/6 mice (11-12 weeks-old) were injected with a single dose of Ex-4 or KGF (1 mg/kg) and sacrificed 1, 5 or 20 h later by CO 2 inhalation. RNA was isolated from mucosal scrapings taken from a 2 cm piece of the jejunum. Microarray analysis was performed (www.pmgenomics.ca) using the Illumina Mouse Whole Genome (WG-6V2) Beadchip. See also Supplemental Experimental Procedures. The accession number for the microarray data is GSE63841. Data was checked for overall quality using R (v3.0.2) with the Bioconductor framework and the LUMI package. Data was then imported in GeneSpring v12.6.1 for analysis.
During import, the data was normalized using a standard (for Illumina arrays) quantile normalization followed by a "per probe" median centered normalization. All data analysis and 
